Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-methyltryptophan is a synthetic tryptophan derivative that acts as a selective blocker of the amino acid transporter SLC6A14 (ATB0,+) and an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). By blocking SLC6A14, alpha-methyltryptophan induces amino acid starvation, leading to decreased mTOR signaling, autophagy, and apoptosis in SLC6A14-positive cancer cells, such as estrogen receptor (ER)-positive breast cancer and colon cancer. Additionally, alpha-methyltryptophan has been shown to function as an effective weight-loss agent in animal models of obesity and metabolic syndrome. In its radiolabeled form, carbon C 11 alpha-methyltryptophan ([11C]AMT), it is utilized as a positron emission tomography (PET) imaging tracer to assess serotonin synthesis and monitor brain tumors, neuroendocrine neoplasms, and melanoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-methyltryptophan.